Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats

Tian Huei Chu, Hoi Hung Chan, Tsung Hui Hu, E. Ming Wang, Yi Ling Ma, Shih Chung Huang, Jian Ching Wu, Yi Chen Chang, Wen Tsan Weng, Zhi Hong Wen, Deng Chyang Wu, Yi Ming Arthur Chen, Ming Hong Tai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC). However, the outcome of HCC patients receiving epirubicin remains unsatisfactory. Moreover, our previous study indicated that celecoxib suppresses HCC progression and liver cancer stemness. This study evaluated the potential of celecoxib to serve as a complementary therapy during epirubicin treatment. Cell proliferation, apoptosis, invasiveness, and anchorage-independent growth were analyzed in hepatoma cells. Therapeutic efficacy was validated in rat orthotopic Novikoff hepatoma. After animal sacrifice, the antitumor mechanism of celecoxib and epirubicin combined therapy was investigated by histological analysis. Celecoxib enhanced the cytotoxic activity of epirubicin in HCC cells by promoting apoptosis. Besides, celecoxib potentiated the antineoplastic function of epirubicin in inhibiting the invasiveness and anchorage-independent growth of HCC cells. Ultrasound monitoring showed that combined therapy was more potent than either therapy alone in perturbing HCC progression. Consistently, the size and weight of dissected HCC tissues from rats receiving combined therapy were smallest among all groups. HCC treated with combined therapy exhibited the highest prevalence of apoptotic cells, which was accompanied by reduced proliferating and angiogenic activities in tumor tissues. Moreover, the expression levels of cancer stemness markers (CD44 and CD133) and drug transporter MDR-1 were significantly diminished in rats receiving combined therapy. Besides, celecoxib treatment increased the infiltration of cytotoxic T lymphocytes (CTLs) and reduced the number of regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and the expression of immune checkpoint PD-L1 in HCC tissues during epirubicin therapy. Celecoxib augmented the therapeutic efficacy while modulated cancer stemness and antitumor immunity. Thus, celecoxib may serve as complementary therapy to improve the outcome of patients with advanced HCC during epirubicin treatment.

Original languageEnglish
Pages (from-to)2567-2580
Number of pages14
JournalCancer Medicine
Volume7
Issue number6
DOIs
Publication statusPublished - Jun 1 2018
Externally publishedYes

Fingerprint

Celecoxib
Experimental Liver Neoplasms
Epirubicin
Hepatocellular Carcinoma
Therapeutics
Complementary Therapies
Neoplasms
Apoptosis

Keywords

  • Antitumor immunity
  • cancer stem cells
  • celecoxib
  • epirubicin
  • hepatocellular carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Chu, T. H., Chan, H. H., Hu, T. H., Wang, E. M., Ma, Y. L., Huang, S. C., ... Tai, M. H. (2018). Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats. Cancer Medicine, 7(6), 2567-2580. https://doi.org/10.1002/cam4.1487

Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats. / Chu, Tian Huei; Chan, Hoi Hung; Hu, Tsung Hui; Wang, E. Ming; Ma, Yi Ling; Huang, Shih Chung; Wu, Jian Ching; Chang, Yi Chen; Weng, Wen Tsan; Wen, Zhi Hong; Wu, Deng Chyang; Chen, Yi Ming Arthur; Tai, Ming Hong.

In: Cancer Medicine, Vol. 7, No. 6, 01.06.2018, p. 2567-2580.

Research output: Contribution to journalArticle

Chu, TH, Chan, HH, Hu, TH, Wang, EM, Ma, YL, Huang, SC, Wu, JC, Chang, YC, Weng, WT, Wen, ZH, Wu, DC, Chen, YMA & Tai, MH 2018, 'Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats', Cancer Medicine, vol. 7, no. 6, pp. 2567-2580. https://doi.org/10.1002/cam4.1487
Chu, Tian Huei ; Chan, Hoi Hung ; Hu, Tsung Hui ; Wang, E. Ming ; Ma, Yi Ling ; Huang, Shih Chung ; Wu, Jian Ching ; Chang, Yi Chen ; Weng, Wen Tsan ; Wen, Zhi Hong ; Wu, Deng Chyang ; Chen, Yi Ming Arthur ; Tai, Ming Hong. / Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats. In: Cancer Medicine. 2018 ; Vol. 7, No. 6. pp. 2567-2580.
@article{16efb42244b0416ebf03bb4deee99378,
title = "Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats",
abstract = "Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC). However, the outcome of HCC patients receiving epirubicin remains unsatisfactory. Moreover, our previous study indicated that celecoxib suppresses HCC progression and liver cancer stemness. This study evaluated the potential of celecoxib to serve as a complementary therapy during epirubicin treatment. Cell proliferation, apoptosis, invasiveness, and anchorage-independent growth were analyzed in hepatoma cells. Therapeutic efficacy was validated in rat orthotopic Novikoff hepatoma. After animal sacrifice, the antitumor mechanism of celecoxib and epirubicin combined therapy was investigated by histological analysis. Celecoxib enhanced the cytotoxic activity of epirubicin in HCC cells by promoting apoptosis. Besides, celecoxib potentiated the antineoplastic function of epirubicin in inhibiting the invasiveness and anchorage-independent growth of HCC cells. Ultrasound monitoring showed that combined therapy was more potent than either therapy alone in perturbing HCC progression. Consistently, the size and weight of dissected HCC tissues from rats receiving combined therapy were smallest among all groups. HCC treated with combined therapy exhibited the highest prevalence of apoptotic cells, which was accompanied by reduced proliferating and angiogenic activities in tumor tissues. Moreover, the expression levels of cancer stemness markers (CD44 and CD133) and drug transporter MDR-1 were significantly diminished in rats receiving combined therapy. Besides, celecoxib treatment increased the infiltration of cytotoxic T lymphocytes (CTLs) and reduced the number of regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and the expression of immune checkpoint PD-L1 in HCC tissues during epirubicin therapy. Celecoxib augmented the therapeutic efficacy while modulated cancer stemness and antitumor immunity. Thus, celecoxib may serve as complementary therapy to improve the outcome of patients with advanced HCC during epirubicin treatment.",
keywords = "Antitumor immunity, cancer stem cells, celecoxib, epirubicin, hepatocellular carcinoma",
author = "Chu, {Tian Huei} and Chan, {Hoi Hung} and Hu, {Tsung Hui} and Wang, {E. Ming} and Ma, {Yi Ling} and Huang, {Shih Chung} and Wu, {Jian Ching} and Chang, {Yi Chen} and Weng, {Wen Tsan} and Wen, {Zhi Hong} and Wu, {Deng Chyang} and Chen, {Yi Ming Arthur} and Tai, {Ming Hong}",
year = "2018",
month = "6",
day = "1",
doi = "10.1002/cam4.1487",
language = "English",
volume = "7",
pages = "2567--2580",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Celecoxib enhances the therapeutic efficacy of epirubicin for Novikoff hepatoma in rats

AU - Chu, Tian Huei

AU - Chan, Hoi Hung

AU - Hu, Tsung Hui

AU - Wang, E. Ming

AU - Ma, Yi Ling

AU - Huang, Shih Chung

AU - Wu, Jian Ching

AU - Chang, Yi Chen

AU - Weng, Wen Tsan

AU - Wen, Zhi Hong

AU - Wu, Deng Chyang

AU - Chen, Yi Ming Arthur

AU - Tai, Ming Hong

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC). However, the outcome of HCC patients receiving epirubicin remains unsatisfactory. Moreover, our previous study indicated that celecoxib suppresses HCC progression and liver cancer stemness. This study evaluated the potential of celecoxib to serve as a complementary therapy during epirubicin treatment. Cell proliferation, apoptosis, invasiveness, and anchorage-independent growth were analyzed in hepatoma cells. Therapeutic efficacy was validated in rat orthotopic Novikoff hepatoma. After animal sacrifice, the antitumor mechanism of celecoxib and epirubicin combined therapy was investigated by histological analysis. Celecoxib enhanced the cytotoxic activity of epirubicin in HCC cells by promoting apoptosis. Besides, celecoxib potentiated the antineoplastic function of epirubicin in inhibiting the invasiveness and anchorage-independent growth of HCC cells. Ultrasound monitoring showed that combined therapy was more potent than either therapy alone in perturbing HCC progression. Consistently, the size and weight of dissected HCC tissues from rats receiving combined therapy were smallest among all groups. HCC treated with combined therapy exhibited the highest prevalence of apoptotic cells, which was accompanied by reduced proliferating and angiogenic activities in tumor tissues. Moreover, the expression levels of cancer stemness markers (CD44 and CD133) and drug transporter MDR-1 were significantly diminished in rats receiving combined therapy. Besides, celecoxib treatment increased the infiltration of cytotoxic T lymphocytes (CTLs) and reduced the number of regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and the expression of immune checkpoint PD-L1 in HCC tissues during epirubicin therapy. Celecoxib augmented the therapeutic efficacy while modulated cancer stemness and antitumor immunity. Thus, celecoxib may serve as complementary therapy to improve the outcome of patients with advanced HCC during epirubicin treatment.

AB - Epirubicin is a chemotherapy agent for hepatocellular carcinoma (HCC). However, the outcome of HCC patients receiving epirubicin remains unsatisfactory. Moreover, our previous study indicated that celecoxib suppresses HCC progression and liver cancer stemness. This study evaluated the potential of celecoxib to serve as a complementary therapy during epirubicin treatment. Cell proliferation, apoptosis, invasiveness, and anchorage-independent growth were analyzed in hepatoma cells. Therapeutic efficacy was validated in rat orthotopic Novikoff hepatoma. After animal sacrifice, the antitumor mechanism of celecoxib and epirubicin combined therapy was investigated by histological analysis. Celecoxib enhanced the cytotoxic activity of epirubicin in HCC cells by promoting apoptosis. Besides, celecoxib potentiated the antineoplastic function of epirubicin in inhibiting the invasiveness and anchorage-independent growth of HCC cells. Ultrasound monitoring showed that combined therapy was more potent than either therapy alone in perturbing HCC progression. Consistently, the size and weight of dissected HCC tissues from rats receiving combined therapy were smallest among all groups. HCC treated with combined therapy exhibited the highest prevalence of apoptotic cells, which was accompanied by reduced proliferating and angiogenic activities in tumor tissues. Moreover, the expression levels of cancer stemness markers (CD44 and CD133) and drug transporter MDR-1 were significantly diminished in rats receiving combined therapy. Besides, celecoxib treatment increased the infiltration of cytotoxic T lymphocytes (CTLs) and reduced the number of regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and the expression of immune checkpoint PD-L1 in HCC tissues during epirubicin therapy. Celecoxib augmented the therapeutic efficacy while modulated cancer stemness and antitumor immunity. Thus, celecoxib may serve as complementary therapy to improve the outcome of patients with advanced HCC during epirubicin treatment.

KW - Antitumor immunity

KW - cancer stem cells

KW - celecoxib

KW - epirubicin

KW - hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85048720751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048720751&partnerID=8YFLogxK

U2 - 10.1002/cam4.1487

DO - 10.1002/cam4.1487

M3 - Article

AN - SCOPUS:85048720751

VL - 7

SP - 2567

EP - 2580

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 6

ER -